{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T10:45:23Z","timestamp":1785926723559,"version":"3.56.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI129709\u201303S1"],"award-info":[{"award-number":["AI129709\u201303S1"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["3U54AG063546-02S2"],"award-info":[{"award-number":["3U54AG063546-02S2"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01 CA260539\u201301"],"award-info":[{"award-number":["U01 CA260539\u201301"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["BLRandD"],"award-info":[{"award-number":["BLRandD"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The BNT162b2 SARS-CoV-2 mRNA vaccination has mitigated the burden of COVID-19 among residents of long-term care facilities considerably, despite being excluded from the vaccine trials. Data on reactogenicity (vaccine side effects) in this population are limited.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aims<\/jats:title>\n                <jats:p>To assess reactogenicity among nursing home (NH) residents. To provide a plausible proxy for predicting vaccine response among this population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We enrolled and sampled NH residents and community-dwelling healthcare workers who received the BNT162b2 mRNA vaccine, to assess local or systemic reactogenicity and antibody levels (immunogenicity).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>NH residents reported reactions at a much lower frequency and lesser severity than the community-dwelling healthcare workers. These reactions were mild and transient with all subjects experiencing more local than systemic reactions. Based on our reactogenicity and immunogenicity data, we developed a linear regression model predicting log-transformed anti-spike, anti-receptor-binding domain (RBD), and neutralizing titers, with a dichotomous variable indicating the presence or absence of reported reactions which revealed a statistically significant effect, with estimated shifts in log-transformed titers ranging from 0.32 to 0.37 (all <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) indicating greater immunogenicity in subjects with one or more reported reactions of varying severity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>With a significantly lower incidence of post-vaccination reactions among NH residents as reported in this study, the BNT162b2 mRNA vaccine appears to be well-tolerated among this vulnerable population. If validated in larger populations, absence of reactogenicity could help guide clinicians in prioritizing vaccine boosters.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Reactogenicity is significantly mild among nursing home residents and overall, subjects who reported post-vaccination reactions developed higher antibody titers.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40520-021-01987-9","type":"journal-article","created":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T18:23:30Z","timestamp":1634322210000},"page":"3151-3160","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents?"],"prefix":"10.1007","volume":"33","author":[{"given":"Oladayo A.","family":"Oyebanji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigid","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Keresztesy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenore","family":"Carias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Wilk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Htin","family":"Aung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri St.","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan C.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher F.","family":"Rowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah D.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl M.","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth E.","family":"Schmader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro B.","family":"Balazs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5503-7888","authenticated-orcid":false,"given":"David H.","family":"Canaday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Gravenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,15]]},"reference":[{"key":"1987_CR1","unstructured":"Pfizer-BioNTech COVID-19 Vaccine. https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/pfizer-biontech-covid-19-vaccine#additional. Accessed 19 June 2021"},{"key":"1987_CR2","unstructured":"Vaccine hesitancy. KFF COVID-19 Vaccine Monitor, January 27, 2021. https:\/\/www.kff.org\/report-section\/kff-covid-19-vaccine-monitor-january-2021-vaccine-hesitancy\/. Accessed 19 June 2021"},{"key":"1987_CR3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmms2101220","author":"L Rosenbaum","year":"2021","unstructured":"Rosenbaum L (2021) Escaping catch-22\u2014overcoming covid vaccine hesitancy. N Engl J Med. https:\/\/doi.org\/10.1056\/nejmms2101220","journal-title":"N Engl J Med"},{"key":"1987_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s10900-021-00984-3","author":"N Biswas","year":"2021","unstructured":"Biswas N, Mustapha T, Khubchandani J et al (2021) The nature and extent of covid-19 vaccination hesitancy in healthcare workers. J Community Health. https:\/\/doi.org\/10.1007\/s10900-021-00984-3","journal-title":"J Community Health"},{"issue":"27","key":"1987_CR5","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/nejmoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N et al (2020) Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med 383:2603\u20132615. https:\/\/doi.org\/10.1056\/nejmoa2034577","journal-title":"N Engl J Med"},{"issue":"25","key":"1987_CR6","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/nejmoa2027906","volume":"383","author":"EE Walsh","year":"2020","unstructured":"Walsh EE, Frenck RW, Falsey AR et al (2020) Safety and immunogenicity of two RNA-based covid-19 vaccine candidates. N Engl J Med 383:2439\u20132450. https:\/\/doi.org\/10.1056\/nejmoa2027906","journal-title":"N Engl J Med"},{"issue":"11","key":"1987_CR7","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1001\/jamainternmed.2020.5084","volume":"180","author":"BKI Helfand","year":"2020","unstructured":"Helfand BKI, Webb M, Gartaganis SL et al (2020) The exclusion of older persons from vaccine and treatment trials for coronavirus disease - missing the target. JAMA Intern Med 180:1546\u20131549. https:\/\/doi.org\/10.1001\/jamainternmed.2020.5084","journal-title":"JAMA Intern Med"},{"issue":"22","key":"1987_CR8","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1056\/NEJMoa2008457","volume":"382","author":"MM Arons","year":"2020","unstructured":"Arons MM, Hatfield KM, Reddy SC et al (2020) Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med 382:2081\u20132090. https:\/\/doi.org\/10.1056\/NEJMoa2008457","journal-title":"N Engl J Med"},{"issue":"21","key":"1987_CR9","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1056\/NEJMoa2005412","volume":"382","author":"TM McMichael","year":"2020","unstructured":"McMichael TM, Currie DW, Clark S et al (2020) Epidemiology of covid-19 in a long-term care facility in King County Washington. N Engl J Med 382:2005\u20132011. https:\/\/doi.org\/10.1056\/NEJMoa2005412","journal-title":"N Engl J Med"},{"issue":"50","key":"1987_CR10","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.15585\/mmwr.mm6950e2","volume":"69","author":"SE Oliver","year":"2020","unstructured":"Oliver SE, Gargano JW, Marin M et al (2020) The advisory committee on immunization practices\u2019 interim recommendation for use of Pfizer-BioNTech covid-19 vaccine \u2014 United States, December 2020. MMWR. Morb Mortal Wkly Rep 69:1922\u20131924. https:\/\/doi.org\/10.15585\/mmwr.mm6950e2","journal-title":"MMWR. Morb Mortal Wkly Rep"},{"key":"1987_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.05.088","author":"BH Bardenheier","year":"2021","unstructured":"Bardenheier BH, Gravenstein S, Blackman C et al (2021) Adverse events following mRNA SARS-CoV-2 vaccination among U.S. nursing home residents. Vaccine. https:\/\/doi.org\/10.1016\/j.vaccine.2021.05.088","journal-title":"Vaccine"},{"key":"1987_CR12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2104849","author":"EM White","year":"2021","unstructured":"White EM et al (2021) Incident SARS-CoV-2 infection among mRNA-vaccinated and unvaccinated nursing home residents. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMc2104849","journal-title":"N Engl J Med"},{"key":"1987_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.smim.2018.10.010","volume":"40","author":"A Ciabattini","year":"2018","unstructured":"Ciabattini A, Nardini C, Santoro F et al (2018) Vaccination in the elderly: the challenge of immune changes with aging. Semin Immunol 40:83\u201394. https:\/\/doi.org\/10.1016\/j.smim.2018.10.010","journal-title":"Semin Immunol"},{"key":"1987_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41541-019-0132-6","volume":"4","author":"C Herv\u00e9","year":"2019","unstructured":"Herv\u00e9 C, Laup\u00e8ze B, Del Giudice G et al (2019) The how\u2019s and what\u2019s of vaccine reactogenicity. NPJ Vaccines 4:39. https:\/\/doi.org\/10.1038\/s41541-019-0132-6","journal-title":"npj Vaccines"},{"key":"1987_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12979-019-0164-9","volume":"16","author":"SN Crooke","year":"2019","unstructured":"Crooke SN, Ovsyannikova IG, Poland GA et al (2019) Immunosenescence and human vaccine immune responses. Immun Ageing 16:25. https:\/\/doi.org\/10.1186\/s12979-019-0164-9","journal-title":"Immun Ageing: I &amp; A"},{"key":"1987_CR16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2102051","author":"T Bradley","year":"2021","unstructured":"Bradley T, Grundberg E, Selvarangan R et al (2021) Antibody responses after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMc2102051","journal-title":"N Engl J Med"},{"key":"1987_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01325-6","author":"JE Ebinger","year":"2021","unstructured":"Ebinger JE, Fert-Bober J, Printsev I et al (2021) Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med. https:\/\/doi.org\/10.1038\/s41591-021-01325-6","journal-title":"Nat Med"},{"issue":"3","key":"1987_CR18","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3390\/life11030249","volume":"11","author":"AG Mathioudakis","year":"2021","unstructured":"Mathioudakis AG, Ghrew M, Ustianowski A et al (2021) Self-reported real-world safety and reactogenicity of covid-19 vaccines: a vaccine recipient survey. Life 11:249. https:\/\/doi.org\/10.3390\/life11030249","journal-title":"Life"},{"issue":"14","key":"1987_CR19","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1056\/nejmc2101667","volume":"384","author":"F Krammer","year":"2021","unstructured":"Krammer F, Srivastava K, Alshammary H et al (2021) Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med 384:1372\u20131374. https:\/\/doi.org\/10.1056\/nejmc2101667","journal-title":"N Engl J Med"},{"key":"1987_CR20","unstructured":"Why do some people get side effects after COVID-19 vaccines? https:\/\/www.yahoo.com\/entertainment\/why-people-side-effects-covid-070229275.html. Accessed 20 July 2021"},{"issue":"8","key":"1987_CR21","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1093\/infdis\/jiaa255","volume":"222","author":"BJ Cowling","year":"2020","unstructured":"Cowling BJ, Thompson MG, Ng TW et al (2020) Comparative reactogenicity of enhanced influenza vaccines in older adults. J Infect Dis 222:1383\u20131391. https:\/\/doi.org\/10.1093\/infdis\/jiaa255","journal-title":"J Infect Dis"},{"key":"1987_CR22","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for grading the severity of adult and pediatric adverse events, Corrected Version 2.1. [July 2017]. https:\/\/rsc.niaid.nih.gov\/sites\/default\/files\/daidsgradingcorrectedv21.pdf. Accessed 25 June 2021"},{"key":"1987_CR23","unstructured":"Local reactions, systemic reactions, adverse events, and serious adverse events: Pfizer-BioNTech COVID-19 Vaccine. https:\/\/www.cdc.gov\/vaccines\/covid-19\/info-by-product\/pfizer\/reactogenicity.html#18-systemic-reactions. Accessed 25 June 2021"},{"key":"1987_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab447","author":"DH Canaday","year":"2021","unstructured":"Canaday DH, Carias L, Oyebanji OA et al (2021) Reduced BNT162b2 mRNA vaccine response in SARS-CoV-2-naive nursing home residents. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciab447","journal-title":"Clin Infect Dis"},{"issue":"9","key":"1987_CR25","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","volume":"184","author":"WF Garcia-Beltran","year":"2021","unstructured":"Garcia-Beltran WF, Lam EC, St Denis K et al (2021) Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell 184:2372-2383.e9. https:\/\/doi.org\/10.1016\/j.cell.2021.03.013","journal-title":"Cell"},{"issue":"12","key":"1987_CR26","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/s41564-020-00813-8","volume":"5","author":"J Seow","year":"2020","unstructured":"Seow J, Graham C, Merrick B et al (2020) Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol 5:1598\u20131607. https:\/\/doi.org\/10.1038\/s41564-020-00813-8","journal-title":"Nat Microbiol"},{"issue":"1","key":"1987_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/trstmh\/tru167","volume":"109","author":"LK Sabra","year":"2015","unstructured":"Sabra LK, Ian M, Eleanor NF (2015) Sex-based differences in immune function and responses to vaccination. Trans R Soc Trop Med Hyg 109:9\u201315. https:\/\/doi.org\/10.1093\/trstmh\/tru167","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"1987_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2021.03.025","author":"M Tr\u00e9-Hardy","year":"2021","unstructured":"Tr\u00e9-Hardy M, Cupaiolo R, Papleux E et al (2021) Reactogenicity, safety and antibody response, after one and two doses of mRNA-1273 in seronegative and seropositive healthcare workers. J Infect. https:\/\/doi.org\/10.1016\/j.jinf.2021.03.025","journal-title":"J Infect"},{"issue":"3","key":"1987_CR29","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1111\/ajt.16516","volume":"21","author":"T Shimabukuro","year":"2021","unstructured":"Shimabukuro T et al (2021) Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech covid-19 vaccine\u2014United States, December 14\u201323, 2020. Am J Transplant 21:1332\u20131337. https:\/\/doi.org\/10.1111\/ajt.16516","journal-title":"Am J Transplant"},{"issue":"2","key":"1987_CR30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1136\/qshc.2008.030114","volume":"19","author":"A King","year":"2010","unstructured":"King A, Daniels J, Lim J et al (2010) Time to listen: a review of methods to solicit patient reports of adverse events. Qual Saf Health Care 19:148\u2013157. https:\/\/doi.org\/10.1136\/qshc.2008.030114","journal-title":"Qual Saf Health Care"},{"key":"1987_CR31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.15585\/mmwr.mm7008e3","volume":"70","author":"J Gee","year":"2021","unstructured":"Gee J, Marquez P, Su J et al (2021) First month of covid-19 vaccine safety monitoring \u2014 United States, December 14, 2020\u2013January 13, 2021. MMWR Morb Mortal Wkly Rep 70:283\u2013288","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1987_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00224-3","author":"C Menni","year":"2021","unstructured":"Menni C, Klaser K, May A et al (2021) Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the covid symptom study app in the UK: a prospective observational study. Lancet Infect Dis. https:\/\/doi.org\/10.1016\/S1473-3099(21)00224-3","journal-title":"Lancet Infect Dis"},{"key":"1987_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab381","author":"M Lisa","year":"2021","unstructured":"Lisa M, Marcel A, Wiebke M et al (2021) Age-dependent immune response to the Biontech\/Pfizer BNT162b2 covid-19 vaccination. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciab381","journal-title":"Clin Infect Dis"},{"key":"1987_CR34","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1002\/(sici)1099-1557(199710)6:3+3.3.co;2-w","volume":"6","author":"S Joelson","year":"1997","unstructured":"Joelson S, Joelson IB, Wallander MA (1997) Geographical variation in adverse event reporting rates in clinical trials. Pharmacoepidemiol Drug Saf. 6:S31-5. https:\/\/doi.org\/10.1002\/(sici)1099-1557(199710)6:3+3.3.co;2-w","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"10","key":"1987_CR35","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1093\/rheumatology\/keaa043","volume":"59","author":"D Keebler","year":"2020","unstructured":"Keebler D, Teng E, Chia J et al (2020) Regional variations in adverse event reporting rates and ACR responses in placebo\/standard-of-care arms of rheumatoid arthritis trials. Rheumatology 59:3023\u20133031. https:\/\/doi.org\/10.1093\/rheumatology\/keaa043","journal-title":"Rheumatology"},{"issue":"3","key":"1987_CR36","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40801-016-0081-6","volume":"3","author":"O Marrero","year":"2016","unstructured":"Marrero O, Hung EY, Hauben M (2016) Seasonal and geographic variation in adverse event reporting. Drugs-real World Outcomes. 3:297\u2013306. https:\/\/doi.org\/10.1007\/s40801-016-0081-6","journal-title":"Drugs-real World Outcomes."},{"key":"1987_CR37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12979-021-00219-y","volume":"18","author":"G Pawelec","year":"2021","unstructured":"Pawelec G, McElhaney J (2021) Unanticipated efficacy of SARS-CoV-2 vaccination in older adults. Immun Ageing 18:7. https:\/\/doi.org\/10.1186\/s12979-021-00219-y","journal-title":"Immun Ageing"}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-021-01987-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40520-021-01987-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-021-01987-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T18:04:49Z","timestamp":1637085889000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40520-021-01987-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,15]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1987"],"URL":"https:\/\/doi.org\/10.1007\/s40520-021-01987-9","relation":{},"ISSN":["1720-8319"],"issn-type":[{"value":"1720-8319","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,15]]},"assertion":[{"value":"11 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Potential conflicts of interest. S. G. and D. H. C. are recipients of investigator-initiated grants to their universities from Pfizer to study pneumococcal vaccines and Sanofi Pasteur and Seqirus to study influenza vaccines. S. G. also does consulting for Seqirus, Sanofi, Merck, Vaxart, Novavax, Novavax and Janssen; has served on the speaker\u2019s bureaus for Seqirus and Sanofi; and reports personal fees from Pfizer and data and safety monitoring board (DSMB) fees from Longevoron. D. H. C. has done consulting work for Seqirus. S. D. B. reports royalties from Wolters-Kluwer, lecture fees from Harvard, and DSMB membership for a trial of zoledronic acid in Parkinson\u2019s patients, outside the submitted work. C. L. K. reports grants from the Bill & Melinda Gates Foundation, the National Institutes of Health, and Veterans Health Administration, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval was obtained from the New England Institutional Review Board. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human and animal rights"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that participants provided informed consent for publication of the data generated from their participation in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}